Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Grants LUCAS™ 2 Chest Compression System 510(k) Clearance In The United States
Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS™ 2, the next-generation LUCAS™ Chest Compression System, has been granted 510(k) market clearance by the U.S. Food and Drug Administration (FDA). Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest.
generic viagra online
Isotopes, The Atomic Clues Used To Solve Crimes, Date Ancient Artifacts And Identify Chemicals
Whether it"s the summer grass that tickles your feet or the red Bordeaux smacking on your palette, nearly every part of the world around you carries special chemical markers. These markers, called isotopes, can tell scientists where the molecules that compose a substance are from, where they traveled, and what happened to them along the way. But doing these analyses has been complex and costly. Now, Stanford chemists have developed a new method to make isotopic analysis easier and less expensive.
News of the day
Senate Begins Debate On FDA Regulation Of Tobacco
The Senate began debate Tuesday on whether to grant the Food and Drug Administration power to regulate tobacco products, Reuters reports. Debate began after an 84-11 procedural vote and could continue into next week. The Democratic-backed bill "would let the FDA oversee the packaging, marketing and manufacturing of cigarettes and other tobacco products, which have been linked to cancer and other illnesses and kill 400,000 Americans each year."
Sexual Health

QIAGEN Launches Novel Product Enabling Non-Invasive Prenatal Diagnostics And Cancer Detection

QIAGEN announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The new QIAamp Circulating Nucleic Acid Kit is expected to significantly facilitate the corresponding biomarker research and the introduction of novel molecular tests in prenatal diagnostics which can replace risky, invasive procedures such as amniocentesis. Free circulating DNA and RNA fragments are found in body fluids such as plasma, serum and urine. Scientific research has demonstrated that plasma, in particular, carries a variety of nucleic acids from viruses and different tissues throughout the body, including developing fetuses and tumors. In cancer research, it has also been shown that the concentration of tumor DNA fragments is related to the extent of the disease. The analysis of such DNA and RNA fragments thus not only enables new, virtually non-invasive approaches to the early and highly sensitive detection of different malignancies such as colon or lung cancer, but can also help to monitor the progress of the disease and to assess patient outcomes. Likewise, fetal DNA and RNA fragments circulating in maternal blood can be used for the non-invasive molecular detection of congenital disorders in prenatal diagnostics, an area where QIAGEN also cooperates with Sequenom, Inc. which is a leader in this field. QIAGEN"s new QIAamp Circulating Nucleic Acid Kit for the first time enables the isolation and purification of all types and all sizes of nucleic acids from large-scale plasma and serum samples - and thereby enables unprecedented yields of the isolated molecules and the highest sensitivity of downstream applications. This significantly facilitates the molecular detection of viral infections, where extraction of even the scarcest traces of genetic material is a key requirement for reliable results. Moving forward, the company plans to extend the use of the product to urine samples and the isolation of free circulating miRNA molecules from plasma and serum, which can serve as highly specific biomarkers for cancer. "Our new product brings major improvements to biomarker research for cancer and the development of novel, virtually non-invasive diagnostics based upon nucleic acid fragments circulating in body fluids", said Uwe Oelmueller, Senior Director R&D Diagnostic Sample Preparation and Stabilization at QIAGEN. "The clinical value of this method is well documented, but its widespread implementation and progress in further research have been hampered by the cumbersome and demanding methodology for handling such molecules. The new QIAamp kit removes this bottleneck and will bring significant value for researchers and clinicians." The novel kit is currently available for research use only. The company plans to validate the product for in-vitro diagnostic applications in the United States and Europe. QIAGEN


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009